Literature DB >> 17135978

An analysis of surgical complications, morbidity, and cost calculation in patients undergoing multimodal treatment for operable oropharyngeal carcinoma.

Simon F Preuss1, Gero Quante, Robert Semrau, Rolf-Peter Mueller, Jens Peter Klussmann, Orlando Guntinas-Lichius.   

Abstract

OBJECTIVE/HYPOTHESIS: Tumor control and survival are considered the most important measures of treatment efficacy for patients with primary oropharyngeal squamous cell carcinoma. Furthermore, multimodal treatment protocols should be judged by their complication rates, morbidity, and therapy costs. STUDY
DESIGN: The results of a combined approach of primary surgery and neck dissection with postoperative radio(chemo)therapy were analyzed in retrospective chart review.
METHODS: Two hundred eleven patients' records were analyzed for surgical complications, therapeutic morbidity, and treatment costs.
RESULTS: The rate of postoperative hemorrhage was 4.7%. We observed no fatal complications. Ten percent of our patients required nutrition through percutaneous endoscopic gastrostomy (PEG). Twelve percent of all patients required long-term tracheostomy. The rates of PEG and tracheostomy were significantly higher in patients operated by the transcervical approach. The costs for the combined approach ranged from 10,587 euros (13,377 dollars) to 24,531 euros (30,996 dollars).
CONCLUSIONS: The presented multimodal approach provides a low rate of surgical complications and a tolerable morbidity. Considering the excellent oncologic results, this extensive and more cost-intensive multimodal approach is justified for patients with oropharyngeal cancer.

Entities:  

Mesh:

Year:  2007        PMID: 17135978     DOI: 10.1097/01.mlg.0000246191.90021.5e

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma.

Authors:  Theodoros N Teknos; J Grecula; A Agrawal; M O Old; E Ozer; R Carrau; S Kang; J Rocco; D Blakaj; V Diavolitsis; B Kumar; P Kumar; Q Pan; M Palettas; L Wei; R Baiocchi; P Savvides
Journal:  Invest New Drugs       Date:  2018-12-19       Impact factor: 3.850

Review 2.  The economic burden of head and neck cancer: a systematic literature review.

Authors:  Erika Wissinger; Ingolf Griebsch; Juliane Lungershausen; Talia Foster; Chris L Pashos
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

3.  Lack of adjuvant radiotherapy may increase risk of retropharyngeal node recurrence in patients with squamous cell carcinoma of the head and neck after transoral robotic surgery.

Authors:  Waleed F Mourad; Dukagjin M Blakaj; Rafi Kabarriti; Rebekah Young; Rania A Shourbaji; Jonathan Glanzman; Shyamal Patel; Ravindra Yaparpalvi; Shalom Kalnicki; Madhur K Garg
Journal:  Case Rep Oncol Med       Date:  2013-06-13

4.  Trends and Patterns of Disparities in Oral Cavity and Pharyngeal Cancer in Serbia: Prevalence and Economic Consequences in a Transitional Country.

Authors:  Gordana Djordjevic; Aleksandar Dagovic; Vladimir Ristic; Tatjana Kanjevac; Denis Brajkovic; Milica Popovic
Journal:  Front Pharmacol       Date:  2017-06-16       Impact factor: 5.810

5.  Identification and chemoresistance of cancer stem cells in HPV-negative oropharyngeal cancer.

Authors:  Mehmet Gunduz; Esra Gunduz; Shunji Tamagawa; Keisuke Enomoto; Muneki Hotomi
Journal:  Oncol Lett       Date:  2019-11-21       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.